Stay updated with breaking news from Markl Smythe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
683 Capital Management LLC purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 207,800 shares of the company’s stock, valued at approximately $2,267,000. 683 Capital Management LLC owned 0.42% […]
StockNews.com started coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the stock. PTGX has been the topic of a number of other reports. HC Wainwright lifted their price target on shares of Protagonist Therapeutics from $33.00 […]
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating)’s share price shot up 4.6% during mid-day trading on Friday . The stock traded as high as $26.50 and last traded at $26.20. 429,393 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 1,438,168 shares. The stock had previously closed at […]
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating)’s stock price shot up 3.9% during trading on Thursday . The company traded as high as $18.73 and last traded at $18.73. 149,427 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 1,652,346 shares. The stock had previously closed at $18.02. […]
Protagonist Therapeutics (NASDAQ:PTGX – Get Rating) and Lipocine (NASDAQ:LPCN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Valuation & Earnings This table compares Protagonist Therapeutics and Lipocine’s […]